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for the treatment of rectal cancer we examined the value 
of neoadjuvant chemoradiotherapy in pancreatic cancer in 
a randomized phase II trial. Radiological staging defining 
resectability was basic information prior to randomization 
Abstract
Background In nonrandomized trials, neoadjuvant treat-
ment was reported to prolong survival in patients with pan-
creatic cancer. As neoadjuvant chemoradiation is established 
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in contrast to adjuvant therapy trials resting on pathological 
staging.
Patients and methods Patients with resectable adenocar-
cinoma of the pancreatic head were randomized to primary 
surgery (Arm A) or neoadjuvant chemoradiotherapy fol-
lowed by surgery (Arm B), which was followed by adjuvant 
chemotherapy in both arms. A total of 254 patients were re-
quired to detect a 4.33-month improvement in median over-
all survival (mOS).
Results The trial was stopped after 73 patients; 66 pa-
tients were eligible for analysis. Twenty nine of 33 allocated 
patients received chemoradiotherapy. Radiotherapy was 
completed in all patients. Chemotherapy was changed in 
3 patients due to toxicity. Tumor resection was performed 
in 23 vs. 19 patients (A vs. B). The R0 resection rate was 
48 % (A) and 52 % (B, P = 0.81) and (y)pN0 was 30 % (A) 
vs. 39 % (B, P = 0.44), respectively. Postoperative complica-
tions were comparable in both groups. mOS was 14.4 vs. 
17.4 months (A vs. B; intention-to-treat analysis; P = 0.96). 
After tumor resection, mOS was 18.9 vs. 25.0 months (A 
vs. B; P = 0.79).
Conclusion This worldwide first randomized trial 
for neoadjuvant chemoradiotherapy in pancreatic cancer 
showed that neoadjuvant chemoradiation is safe with respect 
to toxicity, perioperative morbidity, and mortality. Never-
theless, the trial was terminated early due to slow recruit-
ing and the results were not significant. ISRCTN78805636; 
NCT00335543.
Keywords Adenocarcinoma · Chemoradiation · 
Pancreas · Surgical procedures · Operative · Survival
Neoadjuvante Radiochemotherapie mit Gemcitabin/
Cisplatin gefolgt von Resektion versus primärer 
Resektion bei resektablem Pankreaskopfkarzinom
Ergebnisse der ersten prospektiven randomisierten Phase-
II-Studie
Zusammenfassung
Hintergrund Mehrere nichtrandomisierte Studien zeigten, 
dass eine neoadjuvante Therapie das Überleben bei Pati-
enten mit Pankreaskarzinom verlängert. Beim lokal fort-
geschrittenen Rektumkarzinom gehört die neoadjuvante 
Radiochemotherapie bereits zum Therapiestandard. Analog 
wurde der Stellenwert einer Radiochemotherapie beim Pan-
kreaskarzinom in einer randomisierten Phase-II-Studie un-
tersucht. Das prätherapeutische radiologische Staging war 
Grundlage dieser Studie im Gegensatz zu adjuvanten The-
rapiestudien, die auf pathohistologischem Staging basieren.
Patienten und Methoden Patienten mit resektablem Pan-
kreaskopfkarzinom wurden randomisiert in primäre Opera-
tion (Arm A) versus neoadjuvante Radiochemotherapie ge-
folgt von einer Operation (Arm B). Beide Gruppen erhielten 
eine adjuvante Chemotherapie. Es waren 254 Patienten er-
forderlich, um eine Verbesserung des medianen Gesamt-
überlebens von 4,33 Monaten zu erfassen.
Ergebnisse Die Studie wurde wegen zögerlicher Rekru-
tierung nach Einschluss von 73 Patienten beendet. Insge-
samt konnten 66 Patienten ausgewertet werden. Die ihnen 
zugeordnete Radiochemotherapie erhielten 29 von 33 Pa-
tienten. Alle Patienten bekamen die vollständige Bestrah-
lungstherapie. Wegen der Toxizität wurde bei 3 Patienten 
die Chemotherapie reduziert. Eine Pankreastumorresektion 
erhielten 23 vs. 19 Patienten (A vs. B). Die R0-Resektions-
rate betrug 48 % (A) und 52 % (B, P = 0,81). Bei 30 % (A) 
versus 39 % (B, P = 0,44) der resezierten Patienten waren 
keine Lymphknotenmetastasen vorhanden. Die postoperati-
ven Komplikationen waren in beiden Gruppen vergleichbar. 
Das mediane Gesamtüberleben betrug 14,4 vs. 17,4 Monate 
(A vs. B; „Intention-to-treat“-Analyse; P = 0,96). Nach Pan-
kreastumorresektion stieg das Gesamtüberleben auf 18,9 vs. 
25,0 Monate (A vs. B; P = 0,79).
Schlussfolgerung Diese weltweit erste randomisierte 
Studie zur neoadjuvanten Radiochemotherapie beim Pank-
reaskopfkarzinom war in Bezug auf Toxizität sowie peri-
operative Morbidität und Mortalität gut durchführbar. Die 
Ergebnisse sind jedoch nicht signifikant, da diese randomi-
sierte Studie vorzeitig wegen mangelnder Rekrutierung be-
endet werden musste. ISRCTN78805636; NCT00335543.
Schlüsselwörter Adenokarzinom · Radiochemotherapie · 
Pankreas · Operative chirurgische Verfahren · Überleben
Survival rates of patients with pancreatic cancer have 
improved only marginally during the last 30 years with a 
5-year survival rate of only 6 % [1]. In contrast, the prog-
nosis of patients with rectal carcinoma has improved sub-
stantially during the same timeframe [2]. This progress was 
due to standardizing surgical therapy [3] worldwide and by 
the implementation of multimodal therapy [4–6]. Moreover, 
in rectal cancer it was found early that a clear circumferen-
tial margin is important and that even margins below 1 mm 
cause a significant increase in the rate of local recurrence 
[7]. All these measures caused a decline in local recurrence 
from 50 % to about 10 % and an increase of 5-year survival 
rates up to more than 50 % worldwide. This progress led 
to the hypothesis that the much poorer prognosis of ductal 
adenocarcinoma of the pancreas might be improved in an 
analogous manner.
Adjuvant therapy has been tested in a series of RCT 
phase III trials, the most important of these are ESPAC-
1, CONKO-001, RTOG 97–04, and ESPAC-3 [8–11]. But 
these trials were still running or results were not yet avail-
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vessels ≤ 180° confirmed by high resolution CT [20]. All 
inclusion criteria are completely enlisted in Table S1.
The protocol was reviewed and funded by Deutsche 
Krebshilfe, approved “Gütesiegel A” by Deutsche Kreb-
sgesellschaft and approved by the ethics committees of 




Chemoradiation and surgery were described in detail in the 
trial protocol. Briefly patients in Arm B received 300 mg/
m2 gemcitabine and 30 mg/m2 cisplatin on days 1, 8, 22, 
and 29 of radiotherapy. Three-dimensional treatment plan-
ning was mandatory for radiotherapy at 1.8 Gy to 55.8 Gy 
(tumor) or 50.4 Gy [regional lymph nodes, planning target 
volume (PTV ≤ 800 ml)] [21]. Dosis modifications in case 
of toxicity of chemotherapy were specified separately for 
gemcitabine and cisplatin. Criteria for patient withdrawal 
were also defined. Six weeks after chemoradiation, a restag-
ing CT scan was scheduled.
Surgery
The surgical procedure was divided into the three steps: 
exploration, tumor resection, and lymph node dissection. At 
exploration, distant metastases had to be ruled out. Local 
resectability was assessed and in case of vascular tumor 
infiltration the decision to resect the tumor with adjacent 
vessels was completely left to the surgeon and the individ-
ual situation.
Adjuvant chemotherapy
In both arms, adjuvant chemotherapy according to the 
CONKO-001 study protocol was recommended in an 
amendment from 2005 [9].
Assessment and follow-up
Resection specimens were graded and classified accord-
ing to the sixth UICC TNM system [22]. Assessment of 
response to neoadjuvant therapy was based on contrast-
enhanced restaging CT scans 6 weeks after completion 
of chemoradiation. RECIST criteria were used to classify 
response [23].
Acute toxicity and adverse effects were reported using 
the NCI common toxicity criteria v2.0 and RTOG/EORTC 
recommendations for classifying late toxic effects of radio-
therapy [24, 25]. Perioperative complications were graded 
by Dindo’s classification [26].
able when the present trial was planned and conducted. The 
results of these trials led to a change in standard treatment 
recommending adjuvant treatment with chemotherapy since 
2007 in Germany [12].
The concept of neoadjuvant rather than adjuvant treat-
ment in pancreatic cancer appears attractive for several rea-
sons. First, up to 30 % of the tumors staged as resectable 
cannot be resected due to undetected metastatic disease or 
underestimated tumor contact to peripancreatic vessels [13]. 
Second, up to 30 % of the patients cannot receive adjuvant 
therapy because of poor post-operative performance status 
[14]. Both groups of patients are not included into adjuvant 
trials, though improving overall survival in both arms (adju-
vant therapy vs. no adjuvant therapy) by simple patient selec-
tion. Neoadjuvant treatment is thought to be better tolerated 
than adjuvant treatment and avoids postsurgical morbidity 
in patients with rapidly metastasizing tumors. Nonrandom-
ized trials using the neoadjuvant approach support this 
rationale: median OS beyond 30 months for patients after 
neoadjuvant treatment and tumor resection were described 
in several retrospective data analyses [15–18].
Therefore, in 1999 we started to plan this multicenter 
randomized phase II study in patients with locally resect-
able cancer or probably locally resectable cancer of the pan-
creatic head with strict imaging eligibility criteria defining 
vascular involvement. To our knowledge, this is the first 
RCT for patients with primary and borderline (meanwhile 
evolved technical term for “probably”) resectable cancer 
of the pancreatic head comparing primary surgery with 
neoadjuvant treatment followed by surgery, starting with 
randomization in 2003. Here, we report the full results of 
this trial, which was not picked up by the majority of the 
research community at the time the trial was conducted. As 
a consequence, the trial could not be completed and there-
fore shows a lack of statistical significance due to the poor 
recruiting rate. On the other hand, the reporting of nega-
tive trials (i.e., a trial with no clear interpretable results) is 
important to improve future trials.
An extended version of this manuscript including a 
detailed description of all methods employed in this study is 
provided as supplementary material.
Patients and methods
Study design and inclusion criteria
Patients with resectable, histology or cytology proven 
adenocarcinoma of the pancreatic head were randomized 
between surgery alone (Arm A) and neoadjuvant chemora-
diation followed by surgery (Arm B; Fig. 1) [19].
Resectability was defined as no organ infiltration except 
the duodenum and maximal involvement of peripancreatic 
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The statistical analysis was performed on all randomly 
assigned patients with pancreatic carcinoma and sufficient 
data. An intention-to-treat analysis calculated overall sur-
vival for all patients from random assignment. The Kaplan–
Meier technique was used defining death by any cause as 
an event for estimating observed survival and the two-sided 
log-rank test to measure levels of significance. Time to pro-
gression was defined as time to first diagnosis of progres-
sion or recurrence or death of any cause and was analyzed 
for all patients. Comparisons between frequencies were 
performed using the “chi-square” oder “χ2”2 test or, when 
Patients were followed up for at least 36 months at 
3-month intervals until 2 years and 6-month intervals 
thereafter.
End points, sample size, and statistical analysis
The primary endpoint of this trial was overall survival. In 
2001, the study was planned in detail and the design was 
made to detect a change in mOS from 9.15 months in Arm A 
to 13.48 months in Arm B. A power of 80 % at the two-sided 
significance level of 5 % was chosen. It was estimated that 
127 patients per arm would be required.
Fig. 1 CONSORT diagram [36] 
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mentation in the case report form sometimes changes first 
impressions. Due to this low number of patients, the power 
for the formal statistical analysis was limited. All eligible 
patients were evaluable for survival. Patients’ characteris-
tics are listed in Table 1.
Treatment
In Arm B, 29 of 33 patients received chemoradiotherapy. 
A total of 3 patients refused and 1 patient was not fit for 
chemoradiation, but all 4 patients underwent surgery. All 
29 patients who underwent chemoradiation completed radio-
therapy and were treated with a median of 55.8 Gy (range 
45.0–57.6 Gy). Three patients had changes in chemotherapy 
on day 29 due to leukopenia. One patient received 5-fluo-
rouracil/cisplatin instead of gemcitabine/cisplatin (local 
investigator judgment). All other patients received chemo-
therapy as planned. Toxicity of chemoradiation (Arm B) 
is shown in Table 2. During chemoradiotherapy and until 




Between June 2003 and December 2009, 73 patients were 
recruited in eight university hospitals and tertiary referral 
centers in Germany and Switzerland. In December 2009, 
enrollment was terminated because of the poor recruitment 
rate. Seven patients (4 Arm A; 3 Arm B) were deemed ineli-
gible because of withdrawal of consent, lack of data, and 
other tumor entity (Fig. 1). Two patients had metastases at 
randomization (n = 1 distant lymph nodes, n = 1 liver), both 
in Arm B. These patients were not excluded, as it reflects 
real life, where reviewing of initial data at the time of docu-









Age (years) Median (range) 63.9 (33–76) 65.1 (46–73) 62.5 (33–76) 0.62
Gender Male 35 (53) 17 (52) 18 (55) 0.81
Female 31 (47) 16 (48) 15 (45)
KPS 100 13 (20) 7 (21) 6 (18) 0.36
90 36 (54) 15 (46) 21 (64)
80 12 (18) 7 (21) 5 (15)
70 5 (8) 4 (12) 1 (3)
Clinical tumor staging
Clinical T categorya cT1 2 (3) 1 (3) 1 (3) 0.79
cT2 30 (45) 15 (45) 15 (45)
cT3 33 (50) 17 (52) 16 (49)
cT4 1 (2) 0 (0) 1 (3)
Clinical N categorya cN0 52 (79) 30 (91) 22 (67) 0.03
cN1 14 (21) 3 (9) 11 (33)
Clinical M categorya cM0 64 (97) 33 (100) 31 (94) 0.49
cM1 2 (3) 0 (0) 2 (6)
Clinical UICC stagea I 29 (44) 16 (48) 13 (39) 0.31
II 35 (53) 17 (52) 18 (55)
III 0 (0) 0 (0) 0 (0)




Exploratory surgery 36 (55) 17 (52) 19 (58) 0.62
Laparoscopy 28 (42) 15 (46) 13 (39)
Laparotomy 8 (12) 2 (6) 6 (18)
Not done 30 (45) 16 (48) 14 (42)
Biliary stent before 
randomization
Yes 57 (86) 28 (85) 29 (88) 1.0
No 9 (14) 5 (15) 4 (12)
CRT chemoradiation; KPS Karnofsky performance status
aAccording to UICC 2002
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Outcome
The median follow-up for all living patients was 61 months 
(range 37–79 months). There were 29 deaths in Arm A and 
31 deaths in Arm B. At intention-to-treat analysis mOS 
between the two arms was not significantly different for 
all patients irrespective of resection status (Arm A, 14.4 
months; Arm B 17.4 months; P = 0.96; Fig. 2a).
After resection, mOS was 18.9 months (Arm A) versus 
25.0 months (Arm B; P = 0.79; intention-to-treat analy-
sis). Time to progression measured 8.7 versus 8.4 months 
(Arm A versus Arm B; P = 0.95; Fig. 2b).
Pathohistological diagnosis of pancreatic adenocarci-
noma at biopsy was confirmed in 42 of 44 resection speci-
mens. One distal choledochal adenocarcinoma (Arm B) and 
1 duodenal adenocarcinoma (Arm A) were excluded from all 
analyses. R0 resections were achieved in 16 of 33 patients 
versus 17 of 33 patients (Arm A versus Arm B; P = 0.81), 
and mOS was 18.9 months (Arm A) versus 25.9 months 
(Arm B; P = 0.75; Fig. 2c). Nodal status was (y)pN0 in 10 
of 33 patients and 13 of 33 patients in Arm A and Arm B, 
respectively (P = 0.44). (y)pN0-status resulted in signifi-
cantly longer mOS in Arm A (Fig. 2d). Four patients had 
pathologically proven distant metastases resected [Arm A 
n = 2 (lymph node, duodenum); Arm B n = 2 (lymph node)]. 
Pathological results for resected patients are listed in 
Table 4.
surgery 15 severe adverse events were reported, mostly 
cholangitis requiring a change of stent (n = 9). Radiological 
response on restaging CT scan was rarely seen (n = 4 partial 
response), whereas most patients had no change (n = 8) or 
progression (n = 12; missing data n = 5).
In the intention-to-treat analysis, in Arm A, 23 of 
33 patients had tumor resection and 5 patients had vas-
cular resections to achieve clinical R0 resection. Ten of 
33 patients had an explorative laparotomy. In Arm B, 19/33 
patients had tumor resection and 4 patients had extended 
surgery to achieve R0 resection. Ten of 33 patients had an 
explorative laparotomy. Four patients had no surgery due to 
progressive disease. Resection rates between the arms were 
not different (P = 0.31). In Arm B, 3 of 4 patients without 
chemoradiation had tumor resection; 1 patient had liver 
metastases at exploration.
Of importance, patients in Arm B did not have elevated 
rates of high-grade post-operative complications (Table 3).
One patient died as the result of an intraoperative myocar-
dial infarction after tumor resection (Arm A) and 1 patient 
died due to sepsis possibly due to cholangitis after explor-
ative laparotomy (Arm A). One patient had insufficiency of 
the pancreaticojejunal anastomosis followed by multiple 
organ dysfunction (grade 4b, Arm A; none in Arm B). The 
most severe post-operative complications after chemora-
diation were grade 3b (intervention under general anesthe-
sia) due to intraabdominal abscess/fluid retention (n = 4) or 
insufficiency of the choledochojejunal anastomosis (n = 1).
In Arm A, 10 of 23 patients had adjuvant chemotherapy 
and in Arm B 7 of 19 patients.
Table 3 Postoperative complications
Dindo’s grade [36]
All (1–5) 1–2 3a/3b 4a/4b 5
Surgery alone 
(Arm A; n = 33)
32 17 9 4 2
As treated (n = 37) Resection 
(n = 26)
23 12 6 4 1
Exploration 
(n = 11)
9 5 3 0 1
CRT and surgery 
(Arm B; n = 33)
22 16 6 0 0
As treated (n = 29) Resection 
(n = 16)
14 9 5 0 0
Exploration 
(n = 9)
8 7 1 0 0
(no surgery 
n = 4)
– – – – –
Total (n = 66) 54 33 15 4 2
Resection 
(n = 42)
37 21 11 4 1
Exploration 
(n = 20)
17 12 4 0 1
No surgery 
(n = 4)
– – – –
CRT chemoradiotherapy
Table 2 Acute toxicitya of chemoradiotherapy
Parameter N Grade
0–2 3 (%) 4 (%)
Leukopenia 29 20 7 (24) 2 (7)
Thrombopenia 29 18 10 (35) 1 (3)
Anemia 29 27 1 (3) 1 (3)
Nausea/vomiting 28 18 10 (36) –
Gastrointestinal bleeding 28 28b – –
Diarrhea 29 28 1 (3) –
Elevated transaminases 29 23 5 (17)c 1 (3)
Elevated bilirubin 28 26 1 (4) 1 (4)d
Elevated alkaline phosphatase 29 24 5 (17) –
Infection 29 24e 5 (17)f –
aToxicity was defined according to the National Cancer Institute 
Common Toxicity Criteria v2.0 [34]b1 of 28 patients grade 2
c4 of 5 patients due to cholangitis
dDue to cholangitis
eGrade1 and 2: n = 7 (5 patients cholangitis, 1 patient noro virus, 
1 patient localization not known)
f4/5 cholangitis, 1 of 5 patients urinary tract infection
13
1 3
Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin
numbers this is a negative trial and no clear conclusion can 
be drawn from underpowered data and whether there is an 
advantage for one therapy strategy or not.
The following issues of a randomized controlled trial for 
resectable pancreatic cancer have to be addressed in future 
trial protocols: working in interdisciplinary teams, pre-
dicting resectability, definition of vascular resection aims, 
definition of criteria for cancelling tumor resection during 
explorative laparotomy, and adjuvant chemotherapy. One of 
the main problems remains how to predict resectable tumor 
stage at diagnosis as 20 % of tumors without contact to the 
peripancreatic vessels at diagnosis were not resected with 
and without neoadjuvant chemoradiation (data not shown). 
Clearly, the new definition of borderline resectable pan-
creatic cancer is helpful, but has to be evaluated in future 
trials. A further point of discussion is the different judg-
ment between centers with reference to cancelling surgery, 
Discussion
The planning of this trial was started in 1999 with activation 
in 2003 before neoadjuvant treatment had become standard 
for other diseases (e.g., rectal carcinoma) and therefore had 
to overcome resistance by physicians and patients likewise 
against the idea of neoadjuvant treatment as such. Addition-
ally, competing adjuvant trials (CONKO-001 [9], ESPAC-3 
[11]) resulted in lower participation. Another issue was 
histological or cytological proof of disease before random-
ization. To overcome this obstacle to recruitment, the pro-
tocol allowed randomization after histological proof during 
explorative laparotomy. However, to our knowledge this 
remains the first planned and evaluated multicenter RCT 
comparing immediate surgery with surgery after neoadju-
vant therapy in resectable pancreatic cancer, defined as vas-
cular abutment of less than 180°. But due to low patient 
Fig. 2 Kaplan–Meier curves (intention to treat analysis) for a overall 
survival, b time to progression, c overall survival after R0 resection, 
and d overall survival according to (y)pN status. CRT chemoradiation; 
O events [a, c, and d deaths or b progression of disease] observed; N 
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with the highest prognostic value of margin status. There-
fore, higher R0 resection rates after neoadjuvant treatment 
are expected to have an impact on survival [17, 18, 28–30].
Neoadjuvant treatment did not show an effect in this 
strongly underpowered trial due to underrecruitment, but 
on the other hand was a suitable instrument for selecting 
patients for surgery. Patients with initially unknown distant 
metastases might be unmasked by preoperative therapy and 
hence spared from surgery [16]. In this trial, all patients with 
neoadjuvant treatment survived at least 3 months, whereas 
after primary surgery 3 of 34 patients died within this time-
frame. Additionally, less severe complications were seen after 
chemoradiation therapy, probably due to induction of fibrosis, 
which improves the suitability of pancreatic tissue for anas-
tomosis. A recent meta-analysis also found similar periopera-
tive morbidity with and without neoadjuvant treatment [18].
Toxicity of chemoradiotherapy was well manageable in 
this trial. The well-known risk of biliary stent dysfunction 
was managed by prompt stent replacement, but was the 
most frequent reason for severe adverse events. Hemato-
logic toxicity of gemcitabine-based CRT is directly related 
to radiotherapy volume and, therefore, volumes were strictly 
limited [31–33]. Additionally, consequent supportive ther-
apy may explain the improved tolerability of treatment in 
this trial compared to others avoiding loss of weight which 
was described to be a negative prognostic factor after neo-
adjuvant chemoradiotherapy [34]. The patients in this trial 
were treated with 3D-conformal plans which have recently 
been shown to be equally effective and not significantly 
more toxic as IMRT plans in the neoadjuvant setting [35].
Furthermore, predicting resectability based on CT scans 
was difficult. Thus, the CONKO-007 (NCT01827553) trial 
will study the role of chemoradiation in borderline resect-
able and nonresectable pancreatic cancer. A panel of highly 
experienced surgeons will review all CT scans before reg-
istering to the trial and at restaging and give their statement 
about resectability. With the experience of such a trial, the 
criteria of R0 resectability will be evaluated and adjusted. 
Then after knowing the significance of chemoradiation for 
locally advanced and borderline resectable pancreatic can-
cer, the next step might be a phase II trial testing the R0 
resectability with neoadjuvant therapy.
Conclusion
Presented in this article are the results of a RCT implicating 
the strategy of multimodal therapy for (borderline) resectable 
pancreatic cancer which was visionary at the time of plan-
ning and conduction of the trial; it was nearly 15 years ahead 
of its time before this approach was again implemented into 
prospective trials in Europe. In the meantime, the conditions 
for conducting interdisciplinary trials have improved much 
as only one center abandoned resection of the tumor after 
detection of distant lymph node metastasis (2 patients) or 
did not proceed to surgery when progression (locally, dis-
tant, clinically) at restaging after chemoradiation was seen 
(data not shown).
The initially mandatory laparoscopy was reclassified as 
optional due to objections of potential trial participants in 
a 2004amendment. Altogether, surgical staging was con-
ducted only in 54 % of all patients and should be considered 
in further trials on preoperative treatment strategies [15].
The closest possible comparison of this trial is with 
adjuvant treatment, especially with the CONKO-001 trial 
conducted in the same population and with an observation 
arm [9, 27]. However, the fundamental difference between 
the reported trial here and adjuvant treatment is that the 
latter only includes patients after resection and pathologi-
cal staging, whereas in this study 24 of 68 patients (35 %) 
had reasons preventing curative resection despite the sug-
gested resectability at staging. Median overall survival in 
the CONKO-001 trial was 20.2 and 22.1 months (control 
versus adjuvant gemcitabine, P = 0.06). This compares well 
with the mOS of patients with resections in this trial (18 and 
25 months; Arm A versus Arm B). In CONKO-001, resec-
tion margin status was a negative prognostic marker in the 
observation arm (mOS 20.8 and 14.1 months R0 versus R1). 
Recent reports about the lack of prognostic significance of 
margins might be related to frequent underreporting of R1 
status because series with high R1 resection rates correlated 
Table 4 Pathological staging











Pathological N categorya (y)pN0 10 13
(y)pN1 13 6
Pathological M categorya (y)pM0 21 17
(y)pM1 2 2








Not specified 0 1
Resection margin R0 16 17
R1 7 2
CRT chemoradiotherapy
aAccording to UICC 2002
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